Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Non-Current Assets (2019 - 2025)

Outset Medical (OM) has disclosed Non-Current Assets for 7 consecutive years, with $13.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 22.54% to $13.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $53.4 million, a 29.25% decrease, with the full-year FY2025 number at $13.6 million, down 22.54% from a year prior.
  • Non-Current Assets was $13.6 million for Q4 2025 at Outset Medical, up from $11.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $58.1 million in Q1 2021 to a low of $11.9 million in Q3 2025.
  • A 5-year average of $32.1 million and a median of $24.4 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: grew 0.39% in 2022, then tumbled 57.33% in 2023.
  • Outset Medical's Non-Current Assets stood at $53.7 million in 2021, then tumbled by 50.67% to $26.5 million in 2022, then decreased by 14.69% to $22.6 million in 2023, then decreased by 22.18% to $17.6 million in 2024, then dropped by 22.54% to $13.6 million in 2025.
  • Per Business Quant, the three most recent readings for OM's Non-Current Assets are $13.6 million (Q4 2025), $11.9 million (Q3 2025), and $13.2 million (Q2 2025).